Alnylam Pharmaceuticals, Inc. ( ALNY ) announced its pipeline growth strategy for the development and commercialization of RNAi therapeutics across three strategic therapeutic areas (STArs) - genetic medicines, cardio-metabolic disease and hepatic infectious disease. <\/p>\n
Alnylam's genetic medicine STAr consists of a broad pipeline of RNAi therapeutics including patisiran (phase III - APOLLO) and revusiran (phase III - ENDEAVOUR), being developed for the treatment of transthyretin-mediated amyloidosis. Additionally, the company reported positive initial data from a phase I study on ALN-AT3 last week. <\/p>\n
The company is advancing ALN-AT3 for the treatment of hemophilia and rare bleeding disorders. Further, the company plans to initiate a phase I\/II study on ALN-CC5 for paroxysmal nocturnal hemoglobinuria. <\/p>\n
Meanwhile, Alnylam intends to commercialize its genetic medicine products in the U.S. and EU, while Genzyme, a Sanofi ( SNY ) company, will develop and commercialize in the rest of the world. <\/p>\n
In its cardio-metabolic disease STAr, Alnylam recently initiated a phase I study on ALN-PCSsc (RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia) with initial data expected in mid-2015. Alnylam has an agreement with The Medicines Company ( MDCO ) for ALN-PCSsc. Alnylam is also advancing other candidates including ALN-AC3 (hypertriglyceridemia), ALN-ANG (hypertriglyceridemia and mixed hyperlipidemia) and ALN-AGT (hypertensive disorders of pregnancy including preeclampsia) among others. <\/p>\n
Finally, Alnylam's hepatic infectious disease STAr includes ALN-HBV for the treatment of hepatitis B viral infection. The company intends to file an investigational new drug (IND) application or an IND equivalent in late 2015. <\/p>\n
Alnylam is looking for partnerships for programs in its cardio-metabolic disease and hepatic infectious disease STArs. At the same time it intends to retain significant product commercialization rights in the U.S. and EU. <\/p>\n
Alnylam expects to provide additional guidance on pipeline programs in its three STArs in Jan 2015. We expect investor focus to remain on Alnylam's pipeline. <\/p>\n
Alnylam currently carries a Zacks Rank #2 (Buy). A better-ranked stock in the health care sector is Amgen Inc. ( AMGN ) carrying a Zacks Rank #1 (Strong Buy). <\/p>\n
ALNYLAM PHARMA (ALNY): Free Stock Analysis Report <\/p>\n
<\/p>\n
Continue reading here: Alnylam Pharmaceuticals, Inc. Continue reading
\nAlnylam Provides Pipeline Update, Growth Strategy - Analyst Blog<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"